US 12,440,544 B2
Cross-reactive epitope for multiple sclerosis
Naresha Saligrama, Stanford, CA (US); and Mark M. Davis, Atherton, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/638,005
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Sep. 3, 2020, PCT No. PCT/US2020/049242
§ 371(c)(1), (2) Date Feb. 24, 2022,
PCT Pub. No. WO2021/046244, PCT Pub. Date Mar. 11, 2021.
Claims priority of provisional application 62/895,805, filed on Sep. 4, 2019.
Prior Publication US 2022/0280620 A1, Sep. 8, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 25/28 (2006.01); C07K 14/005 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01)
CPC A61K 39/0008 (2013.01) [A61P 25/28 (2018.01); C07K 14/005 (2013.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C07K 16/2833 (2013.01); C07K 19/00 (2013.01); G01N 33/505 (2013.01); G01N 33/564 (2013.01); G01N 2800/285 (2013.01)] 20 Claims
 
1. An isolated cross-reactive peptide that comprises or consists of an amino acid sequence of any one of ATFTSYRSWYLA (SEQ ID NO: 1), ANYGKARSWYLK (SEQ ID NO:2), IDRHMYHSYLK (SEQ ID NO:3), DKGQQYRNWFLK (SEQ ID NO: 4), SEQ ID NOs: 23-75, or a variant thereof comprising up to 3 amino acid substitutions or deletions, wherein the isolated cross-reactive peptide is up to 40 amino acids in length.